Distinct immune-effector and metabolic profile of CD8(+) T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors

OBJECTIVES: Rheumatic immune-related adverse events (irAE) such as (poly)arthritis in patients undergoing immune checkpoint inhibitor (ICI) treatment pose a major clinical challenge. ICI therapy improves CD8(+) T cell (CD8) function, but CD8 contributes to chronic inflammation in autoimmune arthriti...

Descripción completa

Detalles Bibliográficos
Autores principales: Benesova, Karolina, Kraus, Franziska Viktoria, Carvalho, Rui A, Lorenz, Holger, Hörth, Christian H, Günther, Janine, Klika, Karel D, Graf, Jürgen, Diekmann, Leonore, Schank, Timo, Christopoulos, Petros, Hassel, Jessica C, Lorenz, Hanns-Martin, Souto-Carneiro, Margarida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Autoinflammatory Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664113/
https://www.ncbi.nlm.nih.gov/pubmed/35922125
http://dx.doi.org/10.1136/ard-2022-222451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664113/
https://www.ncbi.nlm.nih.gov/pubmed/35922125
http://dx.doi.org/10.1136/ard-2022-222451

Ejemplares similares